GL1X · GenesisL1 explorer

Research workbench

Crystal Structure of human JMJD2A complexed with KDOOA011340

Analyse Crystal Structure of human JMJD2A complexed with KDOOA011340 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5F5I
Type
protein
Length
689 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
2.63
Source
Homo sapiens
Molecule
Lysine-specific demethylase 4A
EC
1.14.11.-
UniProt
O75164
Ligands
5V1, NI, ZN, SO4
Pockets
7 · best druggability 0.73

Structure

x-ray diffraction · resolution 2.63 · 2 distinct chains · 30% helix, 24% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ALysine-specific demethylase 4A (EC 1.14.11.-)protein34930% helix, 24% strandO75164
BLysine-specific demethylase 4A (EC 1.14.11.-)protein34031% helix, 25% strandO75164

Ligands and binding sites

  • 5V1 · 2-[[(phenylmethyl)amino]methyl]pyridine-4-carboxylic acid · ligand · 2 copies · chains A, B
  • NI · Nickel (II) ion · metal · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B
  • SO4 · Sulfate ion · ion · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13800.730.8443NI, 5V1
26960.710.7881empty
33600.710.8338NI, 5V1
41000.530.8322empty
51660.430.7424empty

Interfaces

1 interface between chains.

  • A–B · 524 Ų buried · 2 hydrogen bonds · protein-protein

Compared structures

  • 5F5I · Crystal structure of human JMJD2A complexed with KDOOA011340 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.